醒脑静注射液联合丁苯肽胶囊治疗急性脑梗死临床观察

Clinical observation on the combination of Xingnaojing injection and butylphthalide soft capsules in the treatment of acute cerebral infarction

目的分析醒脑静注射液联合丁苯酞软胶囊治疗对急性脑梗死(ACI)患者神经功能恢复及对外周血白细胞介素-23(IL-23)、巨噬细胞炎性蛋白-1α(MIP-1α)水平的影响。方法选取2021-01—2022-12皖北煤电集团总医院收治的118例ACI患者,随机分为对照组与研究组各59例,对照组给予丁苯酞软胶囊治疗,研究组给予醒脑静注射液联合丁苯酞软胶囊治疗,均治疗10 d,比较2组患者的临床疗效、神经功能[美国国立卫生院脑卒中量表(NIHSS)评分、欧洲卒中量表评分(ESS)]、外周血炎性因子[IL-23、MIP-1α水平]、生活质量[Barthel指数量表(BI)评分]以及不良反应发生情况。结果治疗后研究组患者的总有效率为94.92%高于对照组的79.66%(P<0.05),NIHSS评分[(3.15±0.33)分]低于对照组[(4.70±1.08)分],ESS评分[(61.37±7.53)分]高于对照组[(54.54±6.87)分](P<0.05),外周血IL-23水平[(32.82±4.35)ng/L]及MIP-1α水平[(10.37±2.53)ng/L]均低于对照组[(45.36±5.14)ng/L,(18.54±3.87)ng/L](P<0.05),BI评分[(81.02±5.39)分]高于对照组[(65.83±5.57)分](P<0.05)。研究组患者的不良反应发生率(8.47%)与对照组(13.56%)比较无统计学差异(P>0.05),2组患者均未见有明显严重不良反应发生。结论在丁苯酞软胶囊基础上给予ACI患者醒脑静注射液治疗,可提升疗效,有效促进患者神经功能恢复,改善机体炎性反应,提高生活质量,安全性好。

Objective To analyze the effect of Xingnaojing injection combined with butaphthalide soft capsule on the recovery of nerve function and the levels of peripheral blood interleukin-23(IL-23)and macrophage inflammatory protein-1α(MIP-1α)in patients with acute cerebral infarction(ACI).Methods A total of 118 patients with ACI admitted to General Hospital of Wanbei Coal Power Group were enrolled and randomly divided into control group and study group between January 2021 and December 2022,59 cases in each group.The control group was treated with butylphthalein soft capsules,while the study group was additionally treated with Xingnaojing injection for 10 days.The clinical curative effect,nerve function(National Institutes of Health stroke scale(NIHSS),European stroke scale(ESS)),peripheral blood inflammatory factors(IL-23,MIP-1α),quality of life(Barthel index(BI))and the occurrence of adverse reactions were compared between the two groups.Results After treatment,total response rate of study group was higher than that of control group(94.92%vs 79.66%,P<0.05).NIHSS score in study group was lower than that in control group((3.15±0.33)points vs(4.70±1.08)points),while ESS score was higher than that in control group((61.37±7.53)points vs(54.54±6.87)points,P<0.05).The levels of peripheral blood IL-23 and MIP-1αin study group were(32.82±4.35)ng/L and(10.37±2.53)ng/L,which were lower than those in control group((45.36±5.14)ng/L,(18.54±3.87)ng/L,P<0.05),while BI score was higher than that in control group((81.02±5.39)points vs(65.83±5.57)points,P<0.05).There was no significant difference in the incidence of adverse reactions between study group and control group(8.47%vs 13.56%,P>0.05),and there were no significant serious adverse reaction in either group.Conclusion Xingnaojing injection combined with butylphthalide soft capsules can improve curative effect,effectively promote the recovery of nerve function,relieve inflammatory response and improve quality of life in ACI patients,with good safety.